ViiV Healthcare与药品专利池扩展许可协议以促进艾滋病治疗的可及性-动脉网

ViiV Healthcare and Medicines Patent Pool Expand Licensing Agreement to Boost Access to HIV Treatments

GeneOnline 等信源发布 2025-07-14 07:03



可切换为仅中文







by Mark Chiang

马克·蒋

Share To

分享到

An updated licensing agreement between ViiV Healthcare and the Medicines Patent Pool (MPP) aims to enhance access to HIV treatments globally. The expanded collaboration focuses on providing a more patient-centered approach to addressing the needs of individuals living with HIV, according to information released by both organizations..

ViiV Healthcare与药品专利池（MPP）之间更新的许可协议旨在增强全球获得艾滋病毒治疗的机会。根据两家组织发布的信息，此次扩大合作的重点是采取更加以患者为中心的方法来满足艾滋病毒感染者的需求。

The agreement builds on an existing partnership between ViiV Healthcare, a pharmaceutical company specializing in HIV treatment, and MPP, a United Nations-backed public health organization that facilitates access to essential medicines in low- and middle-income countries. This development is expected to broaden the availability of critical HIV therapies by enabling generic manufacturers to produce and distribute these treatments at lower costs.

该协议建立在ViiV Healthcare与MPP现有合作伙伴关系的基础上。ViiV Healthcare是一家专注于HIV治疗的制药公司，而MPP是一家由联合国支持的公共卫生组织，致力于促进低收入和中等收入国家获得基本药物。这一进展预计将通过允许仿制药制造商以更低的成本生产和分发这些治疗药物，从而扩大关键HIV疗法的可及性。

Both parties have emphasized that this step represents progress toward improving global health outcomes for people affected by HIV..

双方都强调，这一步骤代表着在改善受艾滋病毒影响的人们的全球健康结果方面取得了进展。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 14, 2025

日期：2025年7月14日

RFK Jr. Acknowledges MMR Vaccine Effectiveness While Discussing Unverified Treatments

小罗伯特·肯尼迪在讨论未经验证的治疗方法时承认MMR疫苗的有效性

India’s CDMOs Focus on Speed, Quality, and Transparency to Strengthen Role in Global Pharma Supply Chains

印度的CDMO专注于速度、质量和透明度，以加强其在全球制药供应链中的作用。